Journal
PHARMACOGENETICS AND GENOMICS
Volume 20, Issue 4, Pages 274-276Publisher
LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1097/FPC.0b013e328337ce3e
Keywords
5-HTR3A; 5-HTR3B; antipsychotic; BPRS; pharmacogenetics; pharmacogenomics; response; serotonin receptor; treatment outcome
Funding
- Canadian Institutes of Mental Health [MOP-49525, 200508GMH, 93967]
Ask authors/readers for more resources
Earlier results suggest a minor role of variants in the serotonin 3 receptor (HTR3) subunit genes on antipsychotic treatment outcome of schizophrenia patients. In this study, we further investigated the role of the subunits A and B of the HTR3 receptor using 140 schizophrenia patients taking clozapine for 6 months. We have found significant allelic association of clozapine response with three variants in the HTR3A receptor (rs2276302, rs1062613, rs1150226) although only rs1062613 association remained significant after permutations (permutated P = 0.041). Moreover, rs2276302 and rs1062613 have shown nominally significant genotypic association. The two haplotypes composed of rs2276302-rs1062613-rs1150226 were also nominally significant. Taken together, our results suggest that variants in the HTR3A receptor gene can play a role in the treatment outcome of clozapine in schizophrenia patients that are refractory or intolerant of typical antipsychotic therapy. Further studies are necessary to confirm the reported associations. Pharmacogenetics and Genomics 20:274-276 (C) 2010 Wolters Kluwer Health | Lippincott Williams & Wilkins.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available